SIETES :: 93212 citas

Resultados de la búsqueda por DNID REFINAR BÚSQUEDA

1.

Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, Huybrechts KF. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry 2020:1. [Ref.ID 103710]

2.

Douros A, Lix LM, Fralick M, Shah BR, Ronksley PE, Tremblay E, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB, for the Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis A multicenter cohort study. Ann Intern Med 2020:28 de julio. [Ref.ID 103685]

3.

Herman AO. NDMA found in extended-release metformin. Journal Watch 2020:2. [Ref.ID 103641]

4.

Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]

5.

Anderson TS, Odden MC, Penko J, et al.. Generalizability of clinical trials supporting the 2017 American College of Cardiology/American Heart Association blood pressure guideline. JAMA Intern Med 2020;180:795-7. [Ref.ID 103580]

6.

American Heart Association, Heart Failure Society of America, American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology . American Heart Association webpage 2020:. [Ref.ID 103570]

7.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respiratory Medicine 2020;8:11 de marzo. [Ref.ID 103569]

8.

Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:17 de febrero. [Ref.ID 103537]

9.

Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:5 de febrero. [Ref.ID 103514]

10.

Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2020:1. [Ref.ID 103506]

11.

Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics. A systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019;76:31 de julio. [Ref.ID 103245]

12.

Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:29 de agosto. [Ref.ID 103243]

13.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. . Ann Intern Med 2019;171:. [Ref.ID 103236]

14.

Woodcock J. Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.. U.S. Food and Drug Administration 2019:5 de diciembre. [Ref.ID 103218]

15.

Lee M, Sun J, Han M, Cho Y, Lee J-Y, Nam CM, Kang ES. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019;422:noviembre. [Ref.ID 103217]

16.

Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:. [Ref.ID 103193]

17.

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]

18.

Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, Knop FK, Gislason GH, Skov L, Thyssen JP. Association between topical corticosteroid use and type 2 ciabetes in two European population-based adult cohorts. Diabetes Care 2019;42:junio. [Ref.ID 103163]

19.

Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]

20.

Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RD, VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med 2019;380:6 de junio. [Ref.ID 103135]